A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Doxazosin (Cardura)

an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH....

First FDA approval2000-10-18
Generic availableYes · 9 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$54.9M in CY2024 Part D spend3.3M claims · 996K beneficiaries · 329 plans surveyed

Lowest NADAC
$0.069/unit
20 NDCs benchmarked, lowest of all strengths.
Average NADAC
$0.069
Across all dosage forms in distribution.
Highest NADAC
$0.069
Range is tight.
Plans with PA
0 / 329
Zero PA friction — switching is purely formulary.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Doxazosin used for?

an alpha 1 adrenergic antagonist indicated for: • Signs and symptoms of Benign Prostatic Hyperplasia (BPH) • Treatment of HypertensionTreatment of Hypertension 1.1 Benign Prostatic Hyperplasia (BPH....

Is there a generic for Doxazosin?

Yes. 36 ANDAs filed at FDA, 9 generic manufacturers currently shipping.

How much does my plan pay for Doxazosin?

Across 329 Part D plans, Doxazosin averages $0.069/unit (NADAC). Lowest available: $0.069/unit. Highest in distribution: $0.069/unit.

Is Doxazosin on the FDA shortage list?

No. Doxazosin is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

alpha-Adrenergic Blocker5 alternatives in D1
01
Alfuzosin
Brand: Uroxatral
$0.111Lowest NADAC
4Generic mfrs
$39.8MCY24 Part D spend
Compare →
02
Carvedilol
Brand: Coreg
$0.017Lowest NADAC
12Generic mfrs
$265.2MCY24 Part D spend
Compare →
03
Prazosin
alpha-Adrenergic Blocker
$0.085Lowest NADAC
9Generic mfrs
$37.6MCY24 Part D spend
Compare →
04
Silodosin
Brand: RAPAFLO
$0.272Lowest NADAC
10Generic mfrs
$39.6MCY24 Part D spend
Compare →
05
Terazosin
Brand: TEZRULY
$0.109Lowest NADAC
5Generic mfrs
$42.2MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (20 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.